1 / 50

vervolg CASUS

vervolg CASUS. september 2009. inmiddels 6 kuren R-CVP ondergaan restadiering: PR EN NU?. september 2009. watch and wait onderhoud rituximab autologe SCT. onderhoud rituximab 1e lijn. onderhoud rituximab 1e lijn.

arich
Download Presentation

vervolg CASUS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. vervolg CASUS

  2. september 2009 • inmiddels 6 kuren R-CVP ondergaan • restadiering: PR EN NU?

  3. september 2009 • watch and wait • onderhoud rituximab • autologe SCT

  4. onderhoud rituximab 1e lijn

  5. onderhoud rituximab 1e lijn Vidal et al. Rituximabtmaintenancefor the treatment of patient with follicularlymphoma: systematicreview and meta-analysis of randomized trials. J NatlCancerInst 2009; 101: 248-255

  6. onderhoud rituximab 1e lijn Hochster et al. Maintenancerituximabaftercyclophosphamide, vincristine, and prednison prolongsprogression-free survival in advanced indolent lymphoma: results of the randomizedphase III ECOG 1496 study. J ClinOncol 2009; 27 (10): 1607-1614

  7. onderhoud rituximab 1e lijn 3jaar 4.3 jrvs 1.3 jr (p<0.001) Hochster et al. Maintenancerituximabaftercyclophosphamide, vincristine, and prednison prolongsprogression-free survival in advanced indolent lymphoma: results of the randomizedphase III ECOG 1496 study. J ClinOncol 2009; 27 (10): 1607-1614

  8. onderhoud rituximab 1e lijn 3jaar 91% vs 86% (p = 0.08) Hochster et al. Maintenancerituximabaftercyclophosphamide, vincristine, and prednison prolongsprogression-free survival in advanced indolent lymphoma: results of the randomizedphase III ECOG 1496 study. J ClinOncol 2009; 27 (10): 1607-1614

  9. onderhoud rituximab 1e lijn Vidal et al. Rituximabtmaintenancefor the treatment of patient with follicularlymphoma: systematicreview and meta-analysis of randomized trials. J NatlCancerInst 2009; 101: 248-255

  10. onderhoud rituximab 1e lijn PRIMA study?????

  11. autologe SCT in 1e lijn

  12. autologe SCT in 1e lijn Deconinck E, et al. High-dosetherapyfollowedbyautologeouspurgedstem-celltransplantation and doxorubicin-basedchemotherapy in patients with advancedfollicularlymphoma: a randomizedmulticenterstudyby GOELAMS. Blood

  13. autologe in 1e lijn conditionering middels TBI en cyclofosfamide

  14. autologe SCT in 1e lijn plateau na 7 jaar 64% vs 39% (p = 0.004) Deconinck E, et al. High-dosetherapyfollowedbyautologeouspurgedstem-celltransplantation and doxorubicin-basedchemotherapy in patients with advancedfollicularlymphoma: a randomizedmulticenterstudyby GOELAMS. Blood

  15. autologe SCT in 1e lijn 76% vs 80% (NS) Deconinck E, et al. High-dosetherapyfollowedbyautologeouspurgedstem-celltransplantation and doxorubicin-basedchemotherapy in patients with advancedfollicularlymphoma: a randomizedmulticenterstudyby GOELAMS. Blood

  16. autologe SCT in 1e lijn Deconinck E, et al. High-dosetherapyfollowedbyautologeouspurgedstem-celltransplantation and doxorubicin-basedchemotherapy in patients with advancedfollicularlymphoma: a randomizedmulticenterstudyby GOELAMS. Blood

  17. januari 2009 verklaringen: • better survival rates of relapsing patients in the chemotherapy arm • more secondary cancers in HDT arm

  18. januari 2009 progressie…. C/ vroeg recidief (binnen 6 maanden) EN NU?

  19. allo SCT autologe SCT RCHOP plus onderhoud R

  20. allo? Van Besien K, et al. Comparison of autologeous and allogeneic hematopoietic stem celltransplantationforfollicularlymphoma. Blood 2003; 102: 3521

  21. allo? Van Besien K, et al. Comparison of autologeous and allogeneic hematopoietic stem celltransplantationforfollicularlymphoma. Blood 2003; 102: 3521

  22. allo? Van Besien K, et al. Comparison of autologeous and allogeneic hematopoietic stem celltransplantationforfollicularlymphoma. Blood 2003; 102: 3521

  23. allo? Van Besien K, et al. Comparison of autologeous and allogeneic hematopoietic stem celltransplantationforfollicularlymphoma. Blood 2003; 102: 3521

  24. allo? Van Besien K, et al. Comparison of autologeous and allogeneic hematopoietic stem celltransplantationforfollicularlymphoma. Blood 203; 102: 3521

  25. allo? 51% vs 62% vs 55% Van Besien K, et al. Comparison of autologeous and allogeneic hematopoietic stem celltransplantationforfollicularlymphoma. Blood 2003; 102: 3521

  26. allo? Van Besien K, et al. Comparison of autologeous and allogeneic hematopoietic stem celltransplantationforfollicularlymphoma. Blood 2003; 102: 3521

  27. allo? Khouri et al. Eight-yearexperience with allogeneic stem celltransplantationforrelapsedfollicularlymphomaafternonmyeloablativeconditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111

  28. allo? Khouri et al. Eight-yearexperience with allogeneic stem celltransplantationforrelapsedfollicularlymphomaafternonmyeloablativeconditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111

  29. allo? Khouri et al. Eight-yearexperience with allogeneic stem celltransplantationforrelapsedfollicularlymphomaafternonmyeloablativeconditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111

  30. rituximab onderhoud

  31. rituximab onderhoud • 1:1 open label trial fase III trial • nov 1998 – april 2004 • graad 1-3 FL stadium 3-4 • relapse after or resistance to a maximum of 2 nonanthracycline-containing chemotherapy

  32. rituximab onderhoud • remissie-inductie: * CHOP * RCHOP indien na 6 kuren PR of CR 2e randomisatie * observatie 167 * onderhoud rituximab 167 (375 mg/m2 per 3 maanden)

  33. remissie-inductie; response rates Van Oers et al. Rituximabmainteranceimprovesclinicaloutcome of relapsed/resistantfollicularlnon-Hodgkinlymphoma in patients both with and without rituximabduringinduction: results of a prospectiverandomizedphase 3 intergroup trial. Blood 2006;108: 3295

  34. remissie-inductie; PFS median PFS 20.2 vs 33.1 months P < 0.001 Van Oers et al. Rituximabmainteranceimprovesclinicaloutcome of relapsed/resistantfollicularlnon-Hodgkinlymphoma in patients both with and without rituximabduringinduction: results of a prospectiverandomizedphase 3 intergroup trial. Blood 2006;108: 3295

  35. remissie-inductie; OS 3 jrn: 71.9% vs 82.5% (p = 0.096) Van Oers et al. Rituximabmainteranceimprovesclinicaloutcome of relapsed/resistantfollicularlnon-Hodgkinlymphoma in patients both with and without rituximabduringinduction: results of a prospectiverandomizedphase 3 intergroup trial. Blood 2006;108: 3295

  36. rituximab onderhoud; PFS median PFS 51.5 vs 14.9 months P < 0.001 Van Oers et al. Rituximabmainteranceimprovesclinicaloutcome of relapsed/resistantfollicularlnon-Hodgkinlymphoma in patients both with and without rituximabduringinduction: results of a prospectiverandomizedphase 3 intergroup trial. Blood 2006;108: 3295

  37. rituximab onderhoud; OS 3 jaar; 77.1% vs 85.1% (p = 0.011) Van Oers et al. Rituximabmainteranceimprovesclinicaloutcome of relapsed/resistantfollicularlnon-Hodgkinlymphoma in patients both with and without rituximabduringinduction: results of a prospectiverandomizedphase 3 intergroup trial. Blood 2006;108: 3295

  38. rituximab onderhoud; OS 5 jaar OS; 74% vs 64% (p = 0.07) (veel R als salvage) Van Oers et al. Rituximabmainteranceimprovesclinicaloutcome of relapsed/resistantfollicularlnon-Hodgkinlymphoma: Long-termoutcome of the EORTC 20981 phase III randomizedintergroupstudy. Blood 2008; 112: 108: 3295

  39. Overall survival Van Oers et al. Rituximabmainteranceimprovesclinicaloutcome of relapsed/resistantfollicularlnon-Hodgkinlymphoma in patients both with and without rituximabduringinduction: results of a prospectiverandomizedphase 3 intergroup trial. Blood 2006;108: 3295

  40. rituximab onderhoud C/ R maintenance treatment results in a major improvement in PFS (not OS) both after chemotherapy and immunotherapy

  41. rituximab onderhoud Vidal et al. Rituximabtmaintenancefor the treatment of patient with follicularlymphoma: systematicreview and meta-analysis of randomized trials. J NatlCancerInst 2009; 101: 248-255

  42. autologe SCT

  43. autologe SCT

  44. autologe SCT

  45. autologe SCT; PFS

  46. autologe SCT; OS

  47. discussiepunten: • early closure (planned 250-89 evalueerbaar) • pre rituximab tijdperk

  48. Wat indien pt laat recidief had gehad?

  49. allo SCT • autologe SCT • RCHOP met onderhoud R • opnieuw RCVP

More Related